Compare · DXCM vs SOLV
DXCM vs SOLV
Side-by-side comparison of DexCom Inc. (DXCM) and Solventum Corporation (SOLV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SOLV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 2.1x SOLV ($14.08B).
- Over the past year, DXCM is down 8.6% and SOLV is up 11.0% - SOLV leads by 19.6 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 2 for SOLV).
- DXCM has more recent analyst coverage (25 ratings vs 20 for SOLV).
- Company
- DexCom Inc.
- Solventum Corporation
- Price
- $76.65-1.74%
- $81.31-0.39%
- Market cap
- $29.58B
- $14.08B
- 1M return
- +4.76%
- +6.18%
- 1Y return
- -8.64%
- +10.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2024
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 20
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest SOLV
- Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026
- BMO Capital Markets initiated coverage on Solventum with a new price target
- Solventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form SD filed by Solventum Corporation
- Solventum Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Solventum to Participate in the 2026 Jefferies Healthcare Conference
- Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Alban Carlos
- SEC Form 4 filed by Director Cox Carrie Smith
- SEC Form 4 filed by Director Devore Susan D.